XML 78 R70.htm IDEA: XBRL DOCUMENT v3.20.1
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 3 Months Ended
Dec. 31, 2018
Jul. 31, 2018
USD ($)
day
$ / shares
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
Debt Instrument [Line Items]            
Proceeds from long-term debt, net of issuance costs     $ 0 $ 376,000    
Deferred income taxes     0 508,000    
Accrued interest     1,750,000      
Long-term debt     220,616,000   $ 217,991,000  
Convertible debt            
Debt Instrument [Line Items]            
Long-term debt     216,523,000   213,771,000  
Notes payable            
Debt Instrument [Line Items]            
Long-term debt     3,976,000   4,089,000  
Precigen ActoBio Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage           3.00%
Interest expense     235,000 $ 225,000    
Long-term debt     $ 31,446,000      
Trans Ova Genetics, LC | Notes payable | American State Bank            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage     3.95%      
Long-term debt     $ 3,973,000      
Debt instrument, periodic payment     39,000      
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio Inc.            
Debt Instrument [Line Items]            
Aggregate principal amount           $ 30,000,000
3.5% Convertible Notes Due 2023            
Debt Instrument [Line Items]            
Aggregate principal amount   $ 200,000,000 $ 200,000,000      
Proceeds from long-term debt, net of issuance costs   193,958,000        
Debt issuance costs   $ 6,042,000        
Debt instrument, interest rate, stated percentage   3.50% 3.50%      
Conversion rate   58.6622        
Principal amount used in conversion   $ 1,000        
Conversion price (in usd per share) | $ / shares   $ 17.05        
Debt instrument redemption price, percentage   100.00%        
Carrying value of convertible debt   $ 143,723,000 $ 160,077,000   157,560,000  
Equity component of convertible debt, net of issuance costs and deferred taxes   50,235,000        
Deferred income taxes   $ 13,367,000        
Effective interest rate on convertible notes     11.02%      
Convertible notes, unamortized discount and issuance costs     $ 39,923,000      
3.5% Convertible Notes Due 2023 | Minimum            
Debt Instrument [Line Items]            
Common stock price trading days | day   20        
Common stock price consecutive trading days | day   30        
Percentage of common share price over conversion price for conversion   130.00%        
3.5% Convertible Notes Due 2023 | Maximum            
Debt Instrument [Line Items]            
Common stock price trading days | day   5        
Common stock price consecutive trading days | day   5        
Debt instrument redemption price, percentage   98.00%        
Merck Convertible Note            
Debt Instrument [Line Items]            
Aggregate principal amount         $ 25,000,000  
Conversion rate upon IPO 0.90          
Interest rate applicable to IPO conversion event         0.05